Collegium Pharma (COLL) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
August 5, 2020 4:02 PM EDT Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020
Generated $43.9 Million in Cash from Operating Activities in the Second Quarter of 2020
Xtampza ® ER Net Revenue Increased 29% over the Prior Year Period
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Â Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported... More
